Ironwood Pharmaceuticals Stock Performance
| IRWD Stock | USD 1.50 0.01 0.67% |
The company retains a Market Volatility (i.e., Beta) of 1.81, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ironwood Pharmaceuticals will likely underperform. At this point, Ironwood Pharmaceuticals has a negative expected return of -1.6%. Please make sure to check out Ironwood Pharmaceuticals' jensen alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Ironwood Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Ironwood Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Last Split Factor 1194:1000 | Last Split Date 2019-04-02 |
1 | Acquisition by Moukheibir Catherine of 22350 shares of Ironwood Pharmaceuticals subject to Rule 16b-3 | 01/15/2025 |
2 | Acquisition by Currie Mark G of 24311 shares of Ironwood Pharmaceuticals subject to Rule 16b-3 | 01/17/2025 |
3 | Insider Trading | 01/27/2025 |
4 | Ironwood Pharmaceuticals announces workforce reduction - Investing.com | 01/29/2025 |
5 | Disposition of 12052 shares by Greg Martini of Ironwood Pharmaceuticals at 1.76 subject to Rule 16b-3 | 02/10/2025 |
6 | What is Zacks Researchs Forecast for IRWD Q1 Earnings | 02/14/2025 |
7 | Ironwood Pharmaceuticals, Inc. Sees Significant Increase in Short Interest | 02/18/2025 |
8 | Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call | 02/20/2025 |
9 | Brokerages Set Ironwood Pharmaceuticals, Inc. Target Price at 8.60 | 02/27/2025 |
10 | Ironwood Pharmaceuticals, Inc. Q4 2024 Earnings Call Transcript | 02/28/2025 |
11 | Acquisition by Shetzline Michael of 34936 shares of Ironwood Pharmaceuticals subject to Rule 16b-3 | 03/05/2025 |
12 | Acquisition by Denner Alexander J of 2572 shares of Ironwood Pharmaceuticals subject to Rule 16b-3 | 03/18/2025 |
13 | Sarissa Capital Management LP Reduces Stake in Innoviva Inc. | 03/21/2025 |
| Begin Period Cash Flow | 657.9 M |
Ironwood |
Ironwood Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 459.00 in Ironwood Pharmaceuticals on December 25, 2024 and sell it today you would lose (308.50) from holding Ironwood Pharmaceuticals or give up 67.21% of portfolio value over 90 days. Ironwood Pharmaceuticals is currently does not generate positive expected returns and assumes 6.3984% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than Ironwood, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ironwood Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ironwood Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ironwood Pharmaceuticals, and traders can use it to determine the average amount a Ironwood Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2495
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IRWD |
Estimated Market Risk
| 6.4 actual daily | 57 57% of assets are less volatile |
Expected Return
| -1.6 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.25 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ironwood Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ironwood Pharmaceuticals by adding Ironwood Pharmaceuticals to a well-diversified portfolio.
Ironwood Pharmaceuticals Fundamentals Growth
Ironwood Stock prices reflect investors' perceptions of the future prospects and financial health of Ironwood Pharmaceuticals, and Ironwood Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ironwood Stock performance.
| Return On Equity | -5.75 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.37 % | ||||
| Current Valuation | 749.36 M | ||||
| Shares Outstanding | 160.03 M | ||||
| Price To Earning | 18.35 X | ||||
| Price To Book | 2.59 X | ||||
| Price To Sales | 0.68 X | ||||
| Revenue | 351.41 M | ||||
| Gross Profit | 241.46 M | ||||
| EBITDA | 94.85 M | ||||
| Net Income | (1 B) | ||||
| Cash And Equivalents | 504.36 M | ||||
| Cash Per Share | 3.29 X | ||||
| Total Debt | 715.54 M | ||||
| Debt To Equity | 0.78 % | ||||
| Current Ratio | 26.52 X | ||||
| Book Value Per Share | (1.89) X | ||||
| Cash Flow From Operations | 183.43 M | ||||
| Earnings Per Share | 0.01 X | ||||
| Market Capitalization | 238.44 M | ||||
| Total Asset | 471.07 M | ||||
| Retained Earnings | (1.7 B) | ||||
| Working Capital | (42.81 M) | ||||
| Current Asset | 500.2 M | ||||
| Current Liabilities | 76.47 M | ||||
About Ironwood Pharmaceuticals Performance
By analyzing Ironwood Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Ironwood Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ironwood Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ironwood Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 370.02 | 560.14 | |
| Return On Tangible Assets | (2.47) | (2.34) | |
| Return On Capital Employed | (5.58) | (5.30) | |
| Return On Assets | (2.45) | (2.32) | |
| Return On Equity | 2.60 | 2.73 |
Things to note about Ironwood Pharmaceuticals performance evaluation
Checking the ongoing alerts about Ironwood Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ironwood Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ironwood Pharmaceuticals generated a negative expected return over the last 90 days | |
| Ironwood Pharmaceuticals has high historical volatility and very poor performance | |
| Ironwood Pharmaceuticals may become a speculative penny stock | |
| Ironwood Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 351.41 M. Net Loss for the year was (1 B) with profit before overhead, payroll, taxes, and interest of 241.46 M. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Sarissa Capital Management LP Reduces Stake in Innoviva Inc. |
- Analyzing Ironwood Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ironwood Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Ironwood Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ironwood Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ironwood Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ironwood Pharmaceuticals' stock. These opinions can provide insight into Ironwood Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |